Last checked at 18 Mar 2019 12:00
18 March 2019 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
ReNeuron to Present at the Alliance for Regenerative Medicine's
Cell & Gene Therapy Investor Day
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announced that Olav Hellebø, the Company's Chief Executive Officer, will present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day on Thursday, March 21, 2019 at 9:10 am ET (13:10 pm GMT) at The Metropolitan Club in New York City.
A live and archived webcast of the presentation will be available on the Webcasts & Presentations page of the Company's website at www.reneuron.com.
ENDS
ENQUIRIES:
ReNeuron | +44 (0)20 3819 8400 |
Olav Hellebø, Chief Executive Officer | |
Michael Hunt, Chief Financial Officer | |
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Sophie Wills, Tilly Abraham | |
Argot Partners | |
Stephanie Marks, Claudia Styslinger | + 00 1 212 600 1902 |
Stifel Nicolaus Europe Limited | +44 (0) 20 7710 7600 |
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker) | |
Nplus1 Singer Advisory LLP | +44 (0) 20 7496 3000 |
Mark Taylor (Joint Broker) |
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.